Aurobindo Pharma Q4 results: Net profit up 80% to Rs 909 crore

Hyderabad-headquartered Aurobindo Pharma Ltd is a vertically integrated pharmaceutical formulations manufacturer.

Indian pharma major Aurobindo Pharma Ltd on May 25 reported a 80 percent rise in consolidated net profit to Rs 909 crore in the Jan-March quarter of FY24 from Rs 508 crore in the same period a year ago.

The company's consolidated revenue for the quarter grew by 19 percent to Rs 7,580 crore from Rs 6,473 crore in the same quarter a year ago.

EBITDA or Earnings Before Interest, Tax, Depreciation and Amortisation increased 68 percent year-on-year to Rs 1687 crore. EBITDA margin for the quarter expanded to 22.3 percent from 15.5 percent in the same period a year ago.

The company commercialized 4 manufacturing plants including Pen-G, 6-APA, Injectables and Granulation in March 2024 Net Capex of US$ 70 million, including US$ 33 million* towards Pen-G project. The company's total investment for Pen-G project is ~US$ 285 million & Biosimilar project is ~US$ 341 million till March 31st, 2024 Total R&D spend for the quarter is Rs. 392 Crore (5.2% of sales).

“We are extremely delighted to report a strong performance for the quarter and the year, supported by the expansion into the new markets, product launches and stable pricing," said K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company in a press statement. "Our improved capacity utilization has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year, while stabilizing the operations of the recently commercialized facilities,” he added.

Hyderabad-headquartered Aurobindo Pharma Ltd is a vertically integrated pharmaceutical formulations manufacturer. It has 14 formulation manufacturing facilities globally with three in the US, one each in Brazil and Portugal and 11 API manufacturing facilities. The facilities have regulatory approvals from major international agencies.